natgillin/translations-raw huggingface dataset:
A polymorph Form A or polymorph Form B of said salt according to claim 3, said polymorph Form A having characteristic peaks in the XRPD pattern at values of two-theta (Cu Ka, 40 kV, 40 mA) at approximately 9.8, 10.5, 14.9, 17.8, 17.9, 18.5, 19.5, 22.1, 22.6, 26.2, 29.6, and 31.2 degrees and said polymorph Form B having characteristic peaks in the XRPD pattern at values of two-theta (Cu Ka, 40 kV, 40 mA) at approximately 8.9, 10.3, 12.0, 18.3, 20.6, 24.1, 24.5, 26.3, 27.1, and 28.9 degrees. 
Polimorfni Oblik A ili polimorfni Oblik B navedene soli u skladu s patentnim zahtjevom 3, naznačeni time što navedeni polimorfni Oblik A ima karakteristične pikove u XRPD uzorku kod vrijednosti 2θ (Cu Ka, 40 kV, 40 mA) od otprilike 9,8, 10,5, 14,9, 17,8, 17,9, 18,5, 19,5, 22,1, 22,6, 26,2, 29,6, te 31,2°, a navedeni polimorfni Oblik B ima karakteristične pikove u XRPD uzorku kod vrijednosti 2θ (Cu Ka, 40 kV, 40 mA) od otprilike 8,9, 10,3, 12,0, 18,3, 20,6, 24,1, 24,5, 26,3, 27,1, te 28,9°.
The immunogenic polypeptide of any of claims 1-3, wherein the zinc binding residue is amino acid number 1305 based upon alignment with SEQ ID NO: 1. 
Imunogenski polipeptid prema bilo kojem od zahtjeva 1-3, naznačen time da ostatak koji veže cink je amino kiselina broj 1305 zasnovana na svrstavanju sa SEQ ID Br.
A compound of formula (IIIB): 
Spoj sa formulom (II):
The strain, mutant or variant of claim 3, wherein the disease is a member selected from the group consisting of irritable bowel movement, inflammatory bowel disease, e.g. Crohn's disease or ulcerative colitis, irritable bowel syndrome, pouchitis or post infection colitis, gastrointestinal cancer, a systemic disease such as rheumatoid arthritis, an autoimmune disorders due to undesirable inflammatory activity, diarrhoeal disease due to undesirable inflammatory activity, such as Clostridium difficile associated diarrhoea, antibiotics associated diarrhoea, Rotavirus associated diarrhoea or post infective diarrhoea, and combinations thereof. A probiotic formulation comprising the strain, mutant or variant of any of claims 1 to 4, preferably for use as probiotic, in foodstuff and/or as a medicament. 
Formulacija probiotika obuhvaća soj Bifidobacterium bifidum MIMBb75, pohranjen pod brojem DSM24514, za uporabu u liječenju sindroma iritabilnog crijeva, ili bolesti odabrane iz grupe koja se sastoji od gibanja iritabilnog crijeva, upalne bolesti crijeva, Crohnove bolesti, ulceroznog kolitisa, upale crijevne vrećice, postinfekcijskog kolitisa, bolesti s dijarejom, dijareje povezane s Clostridium difficile, i njihovih kombinacija. Formulacija probiotika za uporabu u skladu s patentnim zahtjevom 1, pri čemu navedeno liječenje obuhvaća ublažavanje, sprječavanje i/ili liječenje trbušne boli, nadutosti, zatvora, poremećaja probave, smanjenog gibanja crijeva, pojačanog gibanja crijeva, osjećaja nepotpunog pražnjenja, ili njihovih kombinacija.
The method as claimed in claim 2 or claim 3 wherein at least 98% of the 227Th loaded onto the resin in step ii) is recovered in step x). 
Metoda u skladu s patentnim zahtjevom 2 ili s patentnim zahtjevom 3 pri čemu je najmanje 98% 227Th nanesenog na smolu u koraku ii) obnovljeno u koraku x).
The compound for use according to claim 6, wherein the diseases, disorders, syndromes or conditions associated with the modulation of calcium release-activated calcium (CRAC) channel are selected from the group consisting of inflammatory diseases, autoimmune diseases, allergic disorders, organ transplant, cancer and cardiovascular disorders. 
Spoj za uporabu prema patentnom zahtjevu 6, pri čemu su bolesti, poremećaji, sindromi ili stanja povezani sa modulacijom kalcijeva kanala aktiviranog oslobađanjem kalcija (CRAC) izabrani iz grupe koja se sastoji od inflamatornih bolesti, autoimunih bolesti, alergijskih poremećaja, transplantacije organa, kanrcinoma i kardiovaskularnih poremećaja.
Any compound that can be converted in vivo to provide the bioactive agent (i.e., the compound of formula I) is a prodrug within the scope and spirit of the invention. 
Prolijek je bilo koji spoj koji se in vivo može konvertirati za osiguravanje bioaktivnog agensa (npr., spoj formule I).
genetic diseases due to mutations in Wnt signaling components, such as polyposis coli, osteoporosis-pseudoglioma syndrome, familial exudative vitreoretinopathy, retinal angiogenesis, early coronary disease, tetra-amelia syndrome, Müllerian-duct regression and virilization, SERKAL syndrome, diabetes mellitus type 2, Fuhrmann syndrome, Al-Awadi/Raas-Rothschild/Schinzel phocomelia syndrome, odonto-onycho-dermal dysplasia, obesity, split-hand/foot malformation, caudal duplication syndrome, tooth agenesis, Wilms tumor, skeletal dysplasia, focal dermal hypoplasia, autosomal recessive anonychia, neural tube defects, alpha-thalassemia (ATRX) syndrome, fragile X syndrome, ICF syndrome, Angelman syndrome, Prader-Willi syndrome, Beckwith-Wiedemann Syndrome and Rett syndrome. Furthermore, the compounds and compositions described herein can be used to treat neurological conditions, disorders and/or diseases caused by dysfunction in the Wnt signaling pathway. 
Spoj prema zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, naznačen time da je za upotrebu za liječenje genetske bolesti uzrokovane mutacijama u Wnt signalnim komponentama, pri čemu je genetska bolest odabrana iz skupa koji čine: polipoza coli, osteoporoza-pseudoglioma sindrom, obiteljska eksudativna vitreoretinopatija, retinalna angiogeneza, rana koronarna bolest, sindrom tetra-amelia, regresija i virilizacija Miillerovih kanala, SERKAL sindrom, dijabetes melitus tipa 2, Fuhrmannov sindrom, Al-Awadi/Raas-Rothschild/Schinzelov fokomelija sindrom, odonto-oniho-dermalna displazija, pretilost, malformacija razdvojena ruka/stopalo, sindrom kaudalnog dupliciranja, ageneza zuba, Wilmsov tumor, skeletna displazija, fokalna dermalna hipoplazija, autosomna recesivna anonihija, defekti neuralne cijevi, alfa-talasemija (ATRX) sindrom, sindrom lomljivog kromosoma X, ICF sindrom, Angelmanov sindrom, Prader-Willijev sindrom, Beckwith-Wiedemannov sindrom i Rettov sindrom.
The composition for use as claimed in claim 10, wherein said TRPV1 channel activator is capable of activating a TRPV1 channel in a gastroesophogeal neuron when administered to a subject; and/or said TRPA1 channel activator is capable of activating a TRPA1 channel in a gastroesophogeal neuron when administered to a subject; and/or said ASIC channel activator is capable of activating an ASIC channel in a gastroesophogeal neuron when administered to a subject. 
Pripravak za upotrebu prema zahtjevu 10, naznačen time da navedeni aktivator TRPV1 kanala kada se daje subjektu može aktivirati TRPVI kanal u gastroezofagealnom neuronu; i/ili HR P20171744 T1 navedeni aktivator TRPA1 kanala može aktivirati TRPA1 kanal u gastroezofagealnom neuronu kada se daje subjektu; i/ili navedeni aktivator ASIC kanala može aktivirati ASIC kanal u gastroezofagealnom neuronu kada se daje subjektu.
a heavy chain variable region CDR1 of SEQ ID NO: 7; a heavy chain variable region CDR2 of SEQ ID NO: 14; a heavy chain variable region CDR3 of SEQ ID NO: 21; a light chain variable region CDR1 of SEQ ID NO: 28; a light chain variable region CDR2 of SEQ ID NO: 35; and a light chain variable region CDR3 of SEQ ID NO: 42. 
(DD _CDRI varijabilno područje jakog lanca od SEQ ID NO:7; CDR2 varijabilno područje jakog lanca od SEQ ID NO:14; CDR3 varijabilno područje jakog lanca od SEQ ID NO:21; CDRI varijabilno područje slabog lanca od SEQ ID NO:28; CDR2 varijabilno područje slabog lanca od SEQ ID NO:35; 1 CDR3 varijabilno područje slabog lanca od SEQ ID NO:42.
The present invention thus provides dihydrospiro-[cycloalkylamine]-pyrimidone (or pyrimidione) derivatives represented by formula (I) or salts thereof, solvates thereof or hydrates thereof: 
Prema tome, ovaj izum osigurava dihidrospiro[cikloalkilamin|pirimidonske derivate, prikazane formulom (1), ili njihove soli, njihove solvate ili hidrate: R1
The device according to claim 1, wherein the height of the first gripping element is less than 100 mm. The device according to claim 1, wherein the first gripping element has both its distal and proximal ends directly or indirectly connected to the rigid hose or tube of the nozzle. 
prvi element za hvatanje (110, 210, 310), čija su oba distalni kraj i proksimalni kraj koji su izravno ili neizravno spojeni na krutu cijev ili crijevo (1000) mlaznice (10) i poželjno s osnovicom (101, 201, 301), ima duljinu veću od 200 mm,
The therapeutic and/or prophylactic agent according to claim 1, wherein the tumor is selected from the group consisting of acute myelogenous leukemia, chronic myelogenous leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma, brain tumor, neuroblastoma, glioma, thyroid cancer, myelodysplastic syndrome, head and neck cancer, esophageal cancer, gastric cancer, colorectal cancer, breast cancer, ovarian cancer, lung cancer, pancreatic cancer, liver cancer, gallbladder cancer, skin cancer, malignant melanoma, kidney cancer, renal pelvic and ureteral cancer, bladder cancer, uterine cancer, testicular cancer, prostate cancer, and tumors metastasized from these tumors. 
Terapijsko 1/ili profilaktičko sredstvo namijenjeno upotrebi u liječenju tumora u skladu s patentnim zahtjevom 1, naznačeno time što se tumor bira iz skupine koju čine akutna mijelogena leukemija, kronična mijelogena leukemija, akutna limfocitna leukemija, kronična limfocitna leukemija, Hodgkinov limfom, nehodgkinovski limfom, tumor na mozgu, neuroblastom, gliom, rak štitnjače, mijelodisplastični sindrom, rak glave i vrata, rak jednjaka, rak želuca, kolorektalni rak, rak dojke, rak jajnika, rak pluća, rak gušterače, rak jetre, rak žučnog mjehura, rak kože, zloćudni melanom, rak bubrega, rak nakapnice i mokraćovoda, rak mokraćnog mjehura, rak maternice, rak testisa, rak prostate, te tumori metastazirali iz tih tumora.
The method according to any one of items 27-29, wherein the condition is a skin disease or disorder, sepsis, dermatitis, osteoarthritis, cancer, inflammation, an autoimmune disease, inflammatory bowel disease, a complication from localized or total-body exposure to ionizing radiation, mucositis, acute or chronic organ failure, liver disease, pancreatitis, an eye disorder, a lung disease, or diabetes. 
Farmaceutski pripravak za uporabu prema bilo kojem od zahtjeva 27-29, naznačen time da je stanje kožna bolest ili poremećaj, sepsa, dermatitis, osteoartritis, rak, upala, autoimuna bolest, upalna bolest crijeva, komplikacija od lokaliziranog izlaganja ili izlaganja cijelog tijela ionizirajućem zračenju, mukozitis, akutno ili kronično zatajenje organa, bolest jetre, pankreatitis, poremećaj očiju, plućna bolest, ili dijabetes.
<400> 42 A composition comprising an amount of a MASP-3 inhibitory agent effective to inhibit MASP-3-dependent complement activation for use in treating a subject suffering from paroxysmal nocturnal hemoglobinuria (PNH), wherein said MASP-3 inhibitory agent is a MASP-3 monoclonal antibody or fragment thereof that specifically binds to a portion of human MASP-3 (SEQ ID NO:8). 
Pripravak koji sadrži količinu sredstva za inhibiranje MASP-3 koja djelotvorno inhibira aktiviranje komplementa ovisno o MASP-3, naznačen time što je namijenjen upotrebi u liječenju subjekta koji boluje od paroksizmalne noćne hemoglobinurije (PNH), gdje je navedeno sredstvo za inhibiranje MASP-3 monoklonsko protutijelo protiv MASP-3, ili njegov fragment, koje se specifično veže na dio ljudskog MASP-3 (SEQ ID NO:8).
hydroxyl protecting group such as a silyl protecting group, for example,TBDMS or TES 
hidroksilna zaštitna skupina kao što je silil zaštitna skupina, na primjer, TBDMS ili TES
the amino, aminosulfonyl, and aminocarbonyl optionally are substituted with one or two substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkylsulfonyl, alkenylsulfonyl, and alkynylsulfonyl; 
amino, aminosulfonil i aminokarbonil su opcijski supstituirani s jednim ili dva supstituenta neovisno odabranima iz skupine koju sačinjavaju alkil, alkenil, alkinil, alkilsulfonil, alkenilsulfonil i alkinilsulfonil;
a distal collar (4) with a coupling half at one end, 
- < distalnu spojnicu (4) s polovicom spojnice na jednom kraju,
metformin for use in a method of preventing or treating diabetes mellitus, diseases associated with diabetes mellitus, or complications of diabetes mellitus, wherein (A) and (B) are administered to a patient in need either simultaneously or separately. 
(B) metformina naznačena time da je za uporabu u postupku prevencije ili liječenja dijabetes melitusa, bolesti povezanih sa dijabetes melitusom, ili komplikacijama dijabetes melitusa, pri čemu se (A) i (B) daju pacijentu kojemu je to potrebno bilo istovremeno ili odvojeno.
6 and 7 shows that the motor 12, the gear box 13, the motor block support 14, the spindle 15 and the shaft 16 are not fixedly mounted to the main frame 26, but are allowed to carry out a swivel movement during a closure and opening transfer movement, respectively, of the jaw members 6, 7 . 
Usporedba slika 6 i 7 pokazuje da motor 12, zupčani prijenosnik 13, oslonac bloka motora 14, vratilo 15 i osovina 16 nisu fiksno montirani na glavni okvir 26, već mogu izvoditi rotirajuće kretanje za vrijeme prelaznog kretanja pri otvaranju odnosno pri zatvaranju elemenata čeljusti 6, 7.
A compound having the structure: 
Spoj sa strukturom:
Container as claimed in claim 18, wherein an access section is connected to the wall section at an overlapping portion of the pre-cut part, to facilitate removal of the stiff wall section by the user. 
Spremnik (1) prema jednom od prethodnih patentnih zahtjeva, naznačen time da je dio stijenke (4) postavljen koso u odnosu na obodni smjer (U) pod kutom a.
In place of step 7E, the following procedure was employed: 
Umjesto faze 7B, korišten je sljedeći postupak:
Preferably, the macrocapsule and the rear portion of the fuel element are surrounded by a piece of aluminum foil in a manner similar to that shown in Figure 8. 
Poželjno, makrokapsula 52 1 zadnji dio gorivog elementa okruženi su sa komadom aluminijske folije na sličan način sa onim koji je prikazan na sl. 8.
The cells were then incubated for 72 hours (approximately three doubling times). 
Stanice su inkubirane 72 sata (aproksimativno tri udvostručena vremena).
wherein the wavy line indicates the attachment site to the linker L. 
[image] [image] gdje valovite linije označavaju mjesto priključenja na poveznicu L;
In accordance with a first aspect of the present invention, there is provided a delayed release drug formulation for oral administration to deliver a drug to the colon of a subject, said formulation comprising a core and a coating for the core, the core comprising a drug and the coating comprising an outer layer and an inner layer, wherein the outer layer comprises a mixture of a first polymeric material which is susceptible to attack by colonic bacteria and a second polymeric material which has a pH threshold at pH 6 or above, and wherein the inner layer comprises a third polymeric material that is a non-ionic polymer that is soluble in intestinal fluid or gastrointestinal fluid, and at least one additive selected from a buffer agent and a base. 
Formulacije lijeka s produljenim oslobađanjem za oralnu primjenu za isporuku lijeka u debelo crijevo pacijenta, pri čemu spomenuta formulacija sadrži jezgro, to jezgro sadrži lijek i prevlaku za jezgru, jezgru koja sadrži lijek i ovojnicu koja sadrži vanjski i unutarnji sloj, pri čemu vanjski sloj sadrži smjesu prvog polimernog materijala koji je osjetljiv na napad bakterija debelog crijeva i drugi polimerni materijal koji ima graničnu vrijednost pH na pH 6,5 ili više, 1 pri čemu unutarnji sloj sadrži treći polimerni materijal koji je topiv u crijevnoj tekućini, spomenuti treći polimerni materijal je polimer polikarboksilne kiseline koji je bar djelomično neutraliziran, pri čemu bar 10% skupina karboksilne kiseline polimera polikarboksilne kiseline su u obliku aniona karboksilata.
A composition comprising desmopressin for use in increasing an initial period of undisturbed sleep and/or reducing nocturnal voids in a female patient in need thereof, the composition comprising an orodispersible dose of desmopressin of 10 µg or 25 µg for administration prior to bedtime, wherein the dose is measured as the free base of desmopressin. 
Pripravak, koji sadrži dezmopresin za uporabu kod liječenja nokturije ili noćne poliurije, za smanjenje broja noćnih pražnjenja i/ili za smanjenje noćnog volumena urina i/ili za povećanje početnog razdoblja sna neometanog s noćnim pražnjenjima kod ženskog pacijenta, koji treba takvo liječenje, te pripravak sadrži orodisperzibilnu dozu od 25 mikrograma dezmopresina, naznačen time da se doza mjeri kao slobodna baza dezmopresina, pri čemu se doza uzima od 0,8 do 3 sata prije počinka pacijenta.
The bispecific antibody of claim 8, comprising a H/L chain combination of any one of claims 1-7, and a H/L chain combination that binds a tumor-antigen. 
Bispecifično protutijelo sukladno patentnom zahtjevu 6, koje sadrži kombinaciju H/L lanca iz bilo kojeg od patentnih zahtjeva 1-5 i kombinaciju H/L lanca koja veže tumorski antigen.
The compound according to Claim 1, or a salt or solvate thereof, wherein R3 is a cyano group or a halogen atom. 
Spoj u skladu s patentnim zahtjevom 1, ili njegova sol ili solvat, naznačen time što je R* skupina cijano ili atom halogena.
System according to claim 2, wherein the operating cycles are detected and counted according to the power absorption of said piece of equipment (1). 
Sustav prema zahtjevu 1, naznačen time da se radni ciklusi detektiraju i broje prema apsorpciji napajanja navedenog komada opreme (1).
A toothbrush according to claim 6, in which the bristles on the first and second hemispherical sections, at or adjacent the interface between the sections, are oriented to converge in order to create a protective covering substantially surrounding the interface. 
Četkica za zube (10) sukladno zahtjevu 6 pri čemu su dlačice (28) na prvom i drugom polukružnom dijelu (14,16), na ili uz površinu između dijelova, orijentirane na način da čine zaštitni pokrov koji okružuje sučelje.
Biotin for use thereof in the treatment of multiple sclerosis. 
Biotin naznačen time da je za uporabu za liječenje multiple skleroze.
wherein the compound of Formula (III) or (IIIA) is prepared by reacting 3-nitrophthalic anhydride with a compound of Formula (IV) or (IVA) respectively: 
Postupak u skladu s patentnim zahtjevom 6, naznačen time što se spoj Formule (III) ili (IIIA) dobiva reakcijom 3- nitroftalanhidrida sa spojem Formule (IV) odnosno (IVA):
L is selected from the group consisting of O, S, and N(Rd); wherein Rd is hydrogen, C1-6alkyl, or aryl. 
Farmaceutska dozna formulacija prema patentnom zahtjevu 5, naznačena time što je glidant izabran iz grupe koju čine talk, kukuruzni škrob i silika.
are reacted with trifluoroacetamide and 1,3-dibromo-5,5-dimethylhydantoin in the presence of an alkali salt of tert-butanol in a cyclic ether as a solvent, to give compounds of the formula (6), 
H reagira s trifluoracetamidom i 1,3-dibromo-5,5-dimetilhidantoinom u prisutnosti alkalijske soli fert-butanola u cikličkom eteru kao otapalu, da se dobije spoj s formulom (6), HR P20161547 T1 hE
The tool changing device according to claim 3, wherein said stroke limiting means are constituted by a fluid-operated third actuator designed to produce translational motion of a piston, 
Uređaj prema prethodnim patentnim zahtjevima, naznačen time da se navedena sredstva za ograničavanje udara (29) za vertikalni aktivator (24) sastoje od aktivatora pokretanog fluidom osmišljenoga za proizvodnju translacijskog gibanja klipa (19a)
is piperidinyl substituted with 1 substituent selected from the group consisting of or R2 is R3 is hydrogen, halo, cyano, alkyl, haloalkyl, alkoxy, or haloalkoxy; 
je piperidinil supstituiran sa 1 supstituentom izabranim iz grupe koju čine [image] ili R2 je [image] ili [image]
The bispecific antibody of claim 1, wherein the second binding domain binds to a human CD3e polypeptide or a cynomolgus monkey (cyno) CD3e polypeptide. 
Bispecifično protutijelo prema patentnom zahtjevu 1, naznačeno time, da se prva domena vezanja veže na ljudski polipeptid CD3 ili na majmunski polipeptid CD3 cynomolgus (cyno polipeptid CD3).
The present invention relates to peptides, polynucleotides, vectors and cells that are capable of desensitising or tolerising human individuals to the allergens described above and are therefore useful in the prevention or treatment of dust mite allergy. 
što je svaki različiti polipeptid simultano, odvojeno ili sekvencijski uporabljen u prevenciji ili liječenju alergije na grinje iz kućne prašine po toleranciji, opcionalno pri čemu proizvod dodatno uključuje polipeptide sastava bilo kojeg zahtjeva 2-5.
a pad layer, wherein said pad layer is attached to said base layer. The floor assembly of claim 9, wherein said pad layer is attached to said base layer by at least one of adhesive, thermal bonding, welding, and mechanical attachment. 
Podni sklop u skladu s patentnim zahtjevom 7, naznačen time što je navedeni pokrovni sloj (11) pričvršćen na navedeni osnovni materijal (6) najmanje jednim od ljepila, toplinskog vezanja, zavarivanja, te mehaničkog pričvršćivanja.
SUMMARY OF THE INVENTION In a first aspect, this invention is compounds of the formula 
Razotkrivanje izuma u prvom aspektu, izum je spoj formule gdje.
The process of Claim 12, where L is a sulfonic ester group having the formula - OS(O2)-R, where R is -C1-4alkyl or phenyl, and the phenyl group is optionally substituted with -C1-4alkyl, halo or nitro. 
Postupak prema zahtjevu 12, naznačen time da je L grupa sulfonska estera koji ima formulu -OS(O2)-R, pri čemu je R-C1-4alkil ili fenil, a fenil grupa je po izboru supstituirana s -C1-4alkil, halogen ili nitro.
In another embodiment of the invention, said neurodegenerative disease with Parkinsonian Syndromes is a Parkinson's disease, progressive supranuclear palsy, multiple system atrophy, corticobasal degeneration or a Lewy body dementia. 
Pripravak za uporabu sukladno bilo kojem od zahtjeva 1 do 3, naznačen time, da spomenuta neurodegenerativna bolest sadrži Parkinsonove sindrome su Parkinsonova bolest, progresivna supranuklearna paraliza, višestruka atrofija sustava, kortikobazalni degeneracija ili demencija Lewyjevog tijela.
wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid and wherein said at least one negatively charged counter-ion is a halide ion, preferably a chloride or bromide ion. 
i pri čemu predformulacije oblikuju, ili su u mogućnosti oblikovati najmanje jednu strukturu tekuće kristalinične faze nakon dodira s vodenom tekućinom i pri čemu je navedeni negativno nabijeni protu-ion kloridni ion.
Use of the B cell of claim 12 to make a hybridoma comprising a rearranged immunoglobulin light chain gene sequence derived from the mouse of claim 1, the rearranged sequence comprising a hVλ gene segment, a hJλ gene segment and a mouse Ck gene at an endogenous mouse immunoglobulin k light chain locus, wherein at said locus the k intronic enhancer element upstream of the Ck gene (designated Eki) and the 3' k enhancer downstream of the Ck gene (designated Ek3') are maintained, where the hybridoma expresses an antibody comprising a light chain that comprises a rearranged human Vλ-Jλ sequence and a mouse Ck sequence. 
Hibridom koji se sastoji od preuređene sekvencije gena lakog imunoglobulinskog lanca dobivene iz miša prema zahtjevu 1, preuređene sekvencije koja se sastoji od hVA segmenta gena, hJA segmenta gena funkcionalno povezanog s mišjim CK segmentom gena na mišjem lokusu endogenog lakog x imunoglobulinskog lanca, pri čemu se na spomenutom lokusu održava x element intronskog pojačivača uzlazno od Ck gena (označeno kao EKi1) 1 3'K pojačivač silazno od CK gena, i pri čemu hibridom izražava antitijelo koje se sastoji od lakog lanca koji sadrži preuređenu humanu V2-J2. sekvenciju i mišju Ck sekvenciju.